Medicines Co execs grab a $33M A round to spin out an infectious disease outfit with a pipeline
Turns out, Melinta didn’t bag all of The Medicines Company’s infectious disease work when they executed a buyout deal last fall. There were some preclinical assets in the pipeline as well, and now some of the execs involved have gained the backing of investors to use it to create a pipeline for a startup venture.
Qpex, which announced the closing of a $33 million Series A financing round, now has access to $MDCO‘s beta-lactamase inhibitor technology. Beta-lactamases are a family of enzymes that hydrolyze and thereby inactivate beta-lactam antibiotics – a group of antimicrobials comprising four major groups: penicillins, cephalosporins, monobactams, and carbapenems that are ubiquitous and account for nearly half of all prescribed antibiotics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.